[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxart Inc (VXRT)

Vaxart Inc (VXRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 120,203
  • Shares Outstanding, K 242,835
  • Annual Sales, $ 237,260 K
  • Annual Income, $ 16,330 K
  • EBIT $ 38 M
  • EBITDA $ 46 M
  • 60-Month Beta 1.09
  • Price/Sales 0.51
  • Price/Cash Flow 4.88
  • Price/Book 1.28
  • Price/Earnings ttm 3.33
  • Earnings Per Share ttm 0.15
  • Most Recent Earnings $0.02 on 05/07/26
  • Next Earnings Date 08/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.21
  • Number of Estimates 1
  • High Estimate $-0.21
  • Low Estimate $-0.21
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4500 +10.00%
on 07/24/26
0.6520 -24.08%
on 07/02/26
-0.0250 (-4.81%)
since 06/24/26
3-Month
0.4500 +10.00%
on 07/24/26
0.7890 -37.26%
on 05/04/26
-0.2250 (-31.25%)
since 04/24/26
52-Week
0.3050 +62.30%
on 11/04/25
0.8449 -41.41%
on 01/12/26
+0.0870 (+21.32%)
since 07/24/25

Most Recent Stories

More News
Vaxart to Participate in BTIG Biotechnology Conference 2026

SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary...

VXRT : 0.4950 (-0.90%)
Vaxart Announces Results of Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant...

VXRT : 0.4950 (-0.90%)
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart,...

VXRT : 0.4950 (-0.90%)
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees  Stockholder Group Withdraws Director Nominations SOUTH...

VXRT : 0.4950 (-0.90%)
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase...

VXRT : 0.4950 (-0.90%)
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of...

VXRT : 0.4950 (-0.90%)
Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN...

VXRT : 0.4950 (-0.90%)
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary...

VXRT : 0.4950 (-0.90%)
Vaxart to Participate in BTIG Infectious Disease Day 2026

SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary...

VXRT : 0.4950 (-0.90%)
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Mails Letter to Shareholders Detailing Strength of the Board’s Nominees and Momentum in Advancing Vaxart’s Value Creation Strategy Reinforces that the Dissident’s Nominees Have No Relevant Biotechnology...

VXRT : 0.4950 (-0.90%)

Business Summary

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick...

See More

Key Turning Points

3rd Resistance Point 0.5747
2nd Resistance Point 0.5407
1st Resistance Point 0.5179
Last Price 0.4950
1st Support Level 0.4611
2nd Support Level 0.4271
3rd Support Level 0.4043

See More

52-Week High 0.8449
Fibonacci 61.8% 0.6387
Fibonacci 50% 0.5749
Fibonacci 38.2% 0.5112
Last Price 0.4950
52-Week Low 0.3050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.